REDLAMP 12: Lenalidomide & Rituximab Combo Promising as Initial Treatment for Mantle Cell Lymphoma

Mantle cell lymphoma is a B-cell non-Hodgkin lymphoma that primarily affects the elderly. Approach to initial treatment is highly variable, and decisions are made with consideration of balancing efficacy and toxicity. In this video Dr. Jia Ruan discusses results from a study published in the November 5th issue of the New England Journal of Medicine. The study demonstrated that lenalidomide when taken in combination with rituximab provides an effective treatment option .

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible.

Post a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s